Erik Eliasson

Publications
CV
Public outreach and news

Articles

Article: BREAST CANCER RESEARCH AND TREATMENT. 2023;198(3):499-508

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records

Thoren L; Margolin S; Eliasson E; Bergh J; Lindh JD
Article: HUMAN GENOMICS. 2023;17(1):15

Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences

Zhou Y; Nevosadova L; Eliasson E; Lauschke VMM
Article: THERAPEUTIC DRUG MONITORING. 2023;45(1):45-54

Reproducible Quantification of Unbound Fractions of Four Beta-Lactam Antibiotics: Ultrafiltration Versus Microdialysis of Spiked Healthy Donor Plasma

Beijer G; Clarin L; oestervall J; Barclay V; Eliasson E
Article: SCIENTIFIC REPORTS. 2022;12(1):21891

Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients

Smekal A-K; Furebring M; Eliasson E; Lipcsey M
Article: BREAST CANCER RESEARCH AND TREATMENT. 2021;190(3):451-462

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients

Thoren L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Article: ANNALS OF ONCOLOGY. 2021;32(10):1286-1293

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial

He W; Eriksson M; Eliasson E; Grassmann F; Backlund M; Gabrielson M; Hammarstrom M; Margolin S; Thoren L; Wengstrom Y; Borgquist S; Hall P; Czene K
Article: LAKARTIDNINGEN. 2021;118:20176

[Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure].

Eliasson E; Wadelius M
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2021;65(4):e02029-e02020

Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy

Petersson J; Giske CG; Eliasson E
Article: EUROPEAN RESPIRATORY JOURNAL. 2021;57(3):2003463

Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.

Davies Forsman L; Niward K; Kuhlin J; Zheng X; Zheng R; Ke R; Hong C; Werngren J; Paues J; Simonsson USH; Eliasson E; Hoffner S; Xu B; Alffenaar J-W; Schön T; Hu Y; Bruchfeld J
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2021;87(3):1243-1252

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles

Thoren L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(3):409-419

Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients

Holm J; Mannheimer B; Malmstrom RE; Eliasson E; Lindh JD
Article: PHARMACOGENOMICS JOURNAL. 2020;20(4):579-585

SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions

Hallberg P; Yue Q-Y; Eliasson E; Melhus H; As J; Wadelius M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6):548-557

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer

He W; Grassmann F; Eriksson M; Eliasson E; Margolin S; Thoren L; Hall P; Czene K
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019;85(10):2341-2350

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis

Svensson RJ; Niward K; Forsman LD; Bruchfeld J; Paues J; Eliasson E; Schon T; Simonsson USH
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2019;63(6):e02466-e02418

Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels

Kurland S; Furebring M; Lowdin E; Eliasson E; Nielsen EI; Sjolin J
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019;85(1):194-201

Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients

Haslemo T; Eliasson E; Jukic MM; Ingelman-Sundberg M; Molden E
Article: BMJ OPEN. 2018;8(9):e023899

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study

Forsman LD; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar J-W; Mansjo M; Hoffner S; Xu B; Schon T; Bruchfeld J
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2018;73(10):2838-2845

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting

Niward K; Forsman LD; Bruchfeld J; Chryssanthou E; Carlstrom O; Alomari T; Carlsson B; Pohanka A; Mansjo M; Nordvall MJ; Johansson AG; Eliasson E; Werngren J; Paues J; Simonsson USH; Schon T
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2018;62(5):e00218

Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay

Niward K; Blom LE; Forsman LD; Bruchfeld J; Eliasson E; Schon T; Chryssanthou E; Paues J
Article: CNS DRUGS. 2017;31(11):991-997

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study

Smith RL; Haslemo T; Andreassen OA; Eliasson E; Dahl M-L; Spigset O; Molden E
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2017;121(4):239-245

Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes

Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Article: ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2016;60(10):1425-1436

Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients

Petersson J; Giske CG; Eliasson E
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2016;118(6):408-414

The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes

Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
Article: THERAPEUTIC DRUG MONITORING. 2016;38(1):127-134

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype

Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(6):346-353

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex

Hatta FHM; Lundblad M; Ramsjo M; Kang J-H; Roh H-K; Bertilsson L; Eliasson E; Aklillu E
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2015;116(6):493-498

Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes

Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Article: LAKARTIDNINGEN. 2015;112:DEDP

[Few drugs dominate among clinically important interactions. Swedish register study lists problem drugs].

Holm J; Eiermann B; Eliasson E; Mannheimer B
Article: BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2015;38(12):1975-1979

Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8

Senda A; Mukai Y; Toda T; Hayakawa T; Yamashita M; Eliasson E; Rane A; Inotsume N
Article: BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2015;38(10):1673-1679

Simultaneous Determination Method of Epoxyeicosatrienoic Acids and Dihydroxyeicosatrienoic Acids by LC-MS/MS System

Mukai Y; Toda T; Takeuchi S; Senda A; Yamashita M; Eliasson E; Rane A; Inotsume N
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(11):1375-1383

A limited number of prescribed drugs account for the great majority of drug-drug interactions

Holm J; Eiermann B; Eliasson E; Mannheimer B
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2014;115(4):366-371

Plasma Levels of 25-Hydroxyvitamin D₃ and In Vivo Markers of Cytochrome P450 3A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives

Nylen H; Bjorkhem-Bergman L; Ekstrom L; Roh H-K; Bertilsson L; Eliasson E; Lindh JD; Diczfalusy U
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(8):4941-4943

Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation

Blennow O; Eliasson E; Pettersson T; Pohanka A; Szakos A; El-Serafi I; Hassan M; Ringden O; Mattsson J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(6):695-699

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients

Mannheimer B; Holm J; Koukel L; Bertilsson L; Osby U; Eliasson E
Article: BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2014;37(9):1550-1554

Losartan Competitively Inhibits CYP2C8-Dependent Paclitaxel Metabolism in Vitro

Mukai Y; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69:S25-S32

Therapeutic drug monitoring for tomorrow

Eliasson E; Lindh JD; Malmstrom RE; Beck O; Dahl M-L
Article: PHARMACOGENOMICS. 2013;14(6):613-622

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients

Margolin S; Lindh JD; Thoren L; Xie H; Koukel L; Dahl M-L; Eliasson E
Article: DRUG METABOLISM AND DISPOSITION. 2013;41(4):704-708

Serum Levels of 25-Hydroxyvitamin D and the CYP3A Biomarker 4β-Hydroxycholesterol in a High-Dose Vitamin D Supplementation Study

Bjorkhem-Bergman L; Nylen H; Norlin A-C; Lindh JD; Ekstrom L; Eliasson E; Bergman P; Diczfalusy U
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2013;61(1):1-7

Influence of Simvastatin on the Thromboxane and Prostacyclin Pathways, In Vitro and In Vivo

Skogastierna C; Bjorkhem-Bergman L; Bergman P; Eliasson E; Rane A; Ekstrom L
Article: PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES. 2012;11(12):1797-1801

Vitamin D and drug-metabolising enzymes

Lindh JD; Bjorkhem-Bergman L; Eliasson E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2012;92(2):221-227

UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems

Haslemo T; Loryan I; Ueda N; Mannheimer B; Bertilsson L; Ingelman-Sundberg M; Molden E; Eliasson E
Article: PHARMACOGENOMICS. 2012;13(7):757-762

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele

Andersson ML; Eliasson E; Lindh JD
Article: HEART AND VESSELS. 2011;26(6):628-636

Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide

Skogastierna C; Luksha L; Kublickiene K; Eliasson E; Rane A; Ekstrom L
Article: DRUG METABOLISM AND DISPOSITION. 2011;39(5):933-937

Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D

Lindh JD; Andersson ML; Eliasson E; Bjorkhem-Bergman L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2010;88(3):343-346

Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine

Rosenborg S; Stenberg M; Otto S; Ostervall J; Masquelier M; Yue Q-Y; Bertilsson L; Eliasson E
Article: LAKARTIDNINGEN. 2010;107(22):1459

["Silent" interactions are often missed. Different combinations of pharmaceuticals can result in non-drug effect].

Mannheimer B; Eliasson E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(5):465-474

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients

Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2010;69(4):411-417

Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions

Mannheimer B; Wettermark B; Lundberg M; Pettersson H; von Bahr C; Eliasson E
Article: PHARMACOGENETICS AND GENOMICS. 2010;20(2):77-85

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study

Nordestgaard BG; Kontula K; Benn M; Dahlof B; de Faire U; Edelman JM; Eliasson E; Fyhrquist F; Hille DA; Ibsen H; Lyle PA; Berg K; Sandbergg M; Sethi AA; Wong PH; Os I
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2009;105(5):327-332

Roles of Different CYP Enzymes in the Formation of Specific Fluvastatin Metabolites by Human Liver Microsomes

Toda T; Eliasson E; Ask B; Inotsume N; Rane A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(12):1175-1179

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

Rosenborg SO; Mwinyi J; Andersson M; Baldwin RM; Pedersen RS; Sim SC; Bertilsson L; Ingelman-Sundberg M; Eliasson E
Article: THERAPEUTIC DRUG MONITORING. 2008;30(5):565-569

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy

Mannheimer B; von Bahr C; Pettersson H; Eliasson E
Article: LAKARTIDNINGEN. 2008;105(22):1644-1645

[Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].

Eliasson E
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2008;65(5):767-774

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele;: a pharmacokinetic study in healthy volunteers

Baldwin RM; Ohlsson S; Pedersen RS; Mwinyi J; Ingelman-Sundberg M; Eliasson E; Bertilsson L
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2006;15(3):179-184

Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization

von Euler M; Eliasson E; Öhlén G; Bergman U
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2005;327(4):1052-1057

Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes

Lundblad MS; Stark K; Eliasson E; Oliw E; Rane A
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(49):50949-50955

Use of molecular simulation for mapping conformational CYP2E1 epitopes

Vidali M; Hidestrand M; Eliasson E; Mottaran E; Reale E; Rolla R; Occhino G; Albano E; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2004;60(5):337-342

CYP2C9 genetic variants and losartan oxidation in a Turkish population

Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Article: CHEMICO-BIOLOGICAL INTERACTIONS. 2004;147(2):163-172

NADPH dependent activation of microsomal glutathione transferase 1

Rinaldi R; Aniya Y; Svensson R; Eliasson E; Swedmark S; Shimoji M; Morgenstern R
Article: PHARMACOGENETICS AND GENOMICS. 2003;13(12):715-720

Allelic variants of cytochromes P4502C modify the risk for acute myocardial infarction

Yasar Ü; Bennet AM; Eliasson E; Lundgren S; Wiman B; de Faire U; Rane A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(2):103-109

Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes

Griskevicius L; Yasar Ü; Sandberg M; Hidestrand M; Eliasson E; Tybring G; Hassan M; Dahl ML
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2002;299(1):25-28

Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms

Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;54(4):423-429

Oxidation of celecoxib by polymorphic cytochrome P4502C9 and alcohol dehydrogenase

Sandberg M; Yasar Ü; Strömberg P; Höög JO; Eliasson E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2001;57(10):729-735

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro

Yasar Ü; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Article: DRUG METABOLISM AND DISPOSITION. 2001;29(7):1051-1056

Role of CYP2C9 polymorphism in losartan oxidation

Yasar Ü; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Article: FEBS LETTERS. 1999;464(3):138-142

Amyloid fibril formation by pulmonary surfactant protein C

Gustafsson M; Thyberg J; Näslund J; Eliasson E; Johansson J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;254(3):628-631

Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population

Yasar Ü; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjoqvist F
Article: CHEMICO-BIOLOGICAL INTERACTIONS. 1998;116(1-2):123-141

Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis

Eliasson E; Gardner I; Hume-Smith H; de Waziers I; Beaune P; Kenna JG
Article: JOURNAL OF HEPATOLOGY. 1998;29(5):819-825

Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis

Eliasson E; Stål P; Oksanen A; Lytton S
Article: CHEMICAL RESEARCH IN TOXICOLOGY. 1998;11(8):863-872

Immunochemical identification of hepatic protein adducts derived from estragole

Wakazono H; Gardner I; Eliasson E; Coughtrie MWH; Kenna JG; Caldwell J
Article: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. 1996;333(2):459-465

Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus

Neve EPA; Eliasson E; Pronzato MA; Albano E; Marinari U; IngelmanSundberg M
Article: MOLECULAR PHARMACOLOGY. 1996;50(3):573-582

Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis

Eliasson E; Kenna JG
Article: GASTROENTEROLOGY. 1996;111(1):206-216

Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics

Clot P; Albano E; Eliasson E; Tabone M; Arico S; Israel Y; Moncada C; IngelmanSundberg M
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 1995;293(2):123-131

STABLE EXPRESSION OF HUMAN CYTOCHROME-P450 2E1 IN V79 CHINESE-HAMSTER CELLS

SCHMALIX WA; BARRENSCHEEN M; LANDSIEDEL R; JANZOWSKI C; EISENBRAND G; GONZALEZ F; ELIASSON E; INGELMANSUNDBERG M; PERCHERMEIER M; GREIM H; DOEHMER J
Show more

All other publications

Review: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2022;131(6):452-464

A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing

Zhou Y; Koutsilieri S; Eliasson E; Lauschke VM
Other: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(6):1127-1128

Tribute to Folke Sjoqvist, a Pioneer in Clinical Pharmacology

Dahl M-L; Bergman U; Bertilsson L; Eliasson E; Gustafsson LL; Panagiotidis G; Rane A
Letter: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2017;121(4):215-216

Reply to "Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids'

Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Review: LAKARTIDNINGEN. 2015;112:CW3P

[Beta lactam antibiotics and the question of dose regimen for severe infection. Prolonged infusion theoretically appealing--yet no evidence of clinical benefit].

Leander G; Eliasson E; Hanberger H; Giske C
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2013;45(3):161-175

Rational use of aminoglycosides-Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA)

Hanberger H; Edlund C; Furebring M; Giske CG; Melhus A; Nilsson LE; Petersson J; Sjolin J; Ternhag A; Werner M; Eliasson E
Editorial comment: PHARMACOGENOMICS. 2012;13(16):1887-1891

Karolinska Institutet

Eliasson E; Sim SC; Rane A; Ingelman-Sundberg M
Letter: PHARMACOGENOMICS. 2012;13(14):1561-1562

Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin: author reply

Andersson ML; Eliasson E; Lindh JD
Review: JOURNAL OF INTERNAL MEDICINE. 2010;268(6):540-548

Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice

Mannheimer B; Eliasson E
Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2009;65(10):1055

Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3

Backstrom T; Barkman G; Lindh JD; Eliasson E
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2007;81(6):899-902

The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine:: Focus on antidepressants

Sjoqvist F; Eliasson E
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;80(3):301-302

Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele? Reply

Eliasson E; Lundblad MS
Editorial comment: BMJ-BRITISH MEDICAL JOURNAL. 2006;332(7551):1163-1164

Ethnicity and adverse drug reactions - Personalised drug treatment is getting closer but will not replace good clinical judgment

Eliasson E
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(3):287-288

Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3

Lundblad MS; Ohlsson S; Johansson P; Lafolie P; Eliasson E
Published conference paper: DRUG METABOLISM AND DISPOSITION. 2004;32(5):484-489

The impact of CYP2C9 genetics and oral contraceptives on cytochrome P4502C9 phenotype

Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Review: DRUG METABOLISM AND DISPOSITION. 2002;30(10):1053-1058

Reactive intermediates and the dynamics of glutathione transferases

Rinaldi R; Eliasson E; Swedmark S; Morgenstern R
Letter: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;54(2):183-185

Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity

Yasar Ü; Dahl ML; Christensen M; Eliasson E
Letter: CARCINOGENESIS. 2002;23(4):665

Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk

Yasar Ü; Eliasson E; Dahl ML
Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2002;57(12):915-916

Significant reduction of sertraline plasma levels by carbamazepine and phenytoin

Pihlsgård M; Eliasson E
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;71(1):89-98

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype

Yasar Ü; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Letter: SURGERY. 2001;129(3):384

Mutations of the CYP2C9 gene and the response to warfarin

Yasar U; Oscarson M; Eliasson E; Sjöqvist F
Published conference paper: CHEMICO-BIOLOGICAL INTERACTIONS. 2001;133(1-3):155-158

Microsomal glutathione-S-transferase 1 activation in relation to the cytochrome P450 system

Rinaldi R; Svensson R; Eliasson E; Swedmark S; Morgenstern R
Show more

Employments

Professor/Senior Physician, Department of Laboratory Medicine, Karolinska Institutet, 2012-

Degrees and Education

Docent, Karolinska Institutet, 2000
University Medical Degree, Karolinska Institutet, 1994

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI